Ozempic ‘microdosing' is the new weight-loss trend: Should you try it? [FOX News]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: FOX News
A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. With approximately 70% of American adults meeting the criteria for being obese or overweight, more people are turning to weight loss medications to help them shed pounds. Ozempic is approved for type 2 diabetes , while its counterpart, Wegovy, is approved for treating obesity. Both are made by Novo Nordisk. Eli Lilly also offers a diabetes medication, Mounjaro, as well as a version for weight loss, Zepbound. "Ozempic is the only version among the weekly injectables — Ozempic, Wegovy, Zepbound and Mounjaro — that has the option to ‘hack' the pen for a smaller dose," Dr. Alexandra Sowa, an obesity medicine specialist and founder of SoWell in New York, told Fox News Digital. She is also the author of the book "The Ozempic Revolution" that is set to be released on Jan. 7. Fox News Digital spoke to the experts to get the skinny on this latest trend. Microdosing O
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Lightning Round: Let Lemonade come down, says Jim Cramer [CNBC]CNBC
- Cramer's Lightning Round: ‘I'd be careful' with Novo Nordisk [CNBC]CNBC
- Aro Biotherapeutics Appoints Glenn Crater, MD, as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Drug Company to Share Revenues With Indigenous People Who Donated Their Genes [The New York Times]The New York Times
- Novo Nordisk A/S (NYSE: NVO) was upgraded by analysts at Sanford C. Bernstein from an "underperform" rating to a "market perform" rating.MarketBeat
NVO
Earnings
- 11/7/24 - Beat
NVO
Sec Filings
- 12/20/24 - Form 6-K
- 12/20/24 - Form 6-K
- 12/18/24 - Form 6-K
- NVO's page on the SEC website